The research report presents a comprehensive assessment of the Primary Sclerosing Cholangitis Market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. Primary Sclerosing Cholangitis with 100+ market data Tables, Pie Chat, Graphs & Figures spread.
Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community
USA - English
Share this article
DUBAI, UAE, June 9, 2021 /PRNewswire/ Takeda (TSE: 4502) (NYSE: TAK) has introduced the In Their Shoes platform, an award-winning, immersive simulation program to promote greater awareness and empathy for patients with Inflammatory bowel disease (IBD), a condition to describe Crohn s disease and ulcerative colitis, to a group of healthcare providers in the Middle East the first time.
The subscription-based program launched with a two-day simulation where healthcare providers and Takeda employees learned about the condition most effectively and profoundly: by living with it.
Takeda’s dengue vaccine candidate suggest that it could help with outbreak prevention REPUBLIKA.CO.ID, JAKARTA Takeda Pharmaceutical Company Limited (Takeda) announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual s previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. TIDES enrolled more than 20.000 healthy children and adolescents ages four to 16 years in dengue-endemic countries in Latin America and Asia. Dengue epidemics occur suddenly, and hospitals can become overwhelmed with severe disease cases and people seeking testing, said Managing Director Center for Clinical Management of Dengue and Dengue Haemorrhagic Fever, Negombo General Hospital, Sri Lanka and a primary investigator of the TIDES trial, LakKumar Fernando